Drug makers, Scientists Working For Long COVID Treatments: Reuters
Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,
Roche’s Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population
At the annual congress of the Muscular Dystrophy Association (MDA), Roche Holdings AG (OTC:RHHBY) announced new data for its spinal muscular atrophy…
Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues
Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,
Biogen Exercises Option To Participate Developing Genentech’s Bispecific Antibody, Mosunetuzumab
Biogen Inc (NASDAQ: BIIB) has
CMS Proposes Coverage Of Biogen’s Alzheimer’s Drug, With Conditions Apply
The Centers for Medicare & Medicaid Services (CMS)
Novartis Launches New Share Buyback Program Of Up To $15B
Novartis AG (NYSE: NVS) is launching a
After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial
Atea Pharmaceuticals Inc (NASDAQ: AVIR) said it would
Roche’s Polivy Combo Boosts Survival In Early-Stage Lymphoma Patients
Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 POLARIX study of Polivy (polatuzumab vedotin) with MabThera/Rituxan (rituximab) and the chemotherapy regimen R-CHOP. Data were presented at the American Society of Hematology (ASH) Annual Meeting and Exposition.
Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial
Infinity Pharmaceuticals Inc (NASDAQ: INFI)